Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as a Core Driver of the Remicade Biosimilar Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic period is due to various contributing factors such as the rollout of remicade (infliximab), progress in biotechnology, the expiration of biologics patents, the creation of regulatory pathways, and the pressure to reduce healthcare costs.

What's the Projected Size of the Global Remicade Biosimilar Market by 2029?
In the coming years, the market size for remicade biosimilar is predicted to experience massive growth, eventually reaching a value of "$10.89 billion by 2029, with a compound annual growth rate (CAGR) of 22.2%. This projected growth in the specified period can be credited to factors like patent expiries, the increasing demand for affordable treatment options, the development of biosimilar pipelines, and changes in reimbursement policies and market mergers. Significant trends set to shape this forecast period include physicians' prescription habits, the management of biosimilar lifecycles, naming protocols for biosimilars, their interchangeability, and real-world evidence for biosimilars.

View the full report here:
https://www.thebusinessresearchcompany.com/report/remicade-biosimilar-global-market-report

Top Growth Drivers in the Remicade Biosimilar Industry: What's Accelerating the Market?
The increase in autoimmune diseases is anticipated to boost the expansion of the remicade biosimilar market. Autoimmune diseases, where the immune system erroneously targets and harms the body's tissues and organs, can be treated effectively using remicade biosimilars. These provide a viable therapeutic alternative to manage the symptoms and alleviate inflammation associated with these ailments. For example, data from Public Health Scotland in July 2023 revealed an increase in newly diagnosed multiple sclerosis (MS) patients in 2022, up by 87.2% from 85.7% in 2020. They reported 491 new cases, making the total 6,359 in 2022. Consequently, the increase in autoimmune diseases is fuelling the growth of the remicade biosimilar market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11952&type=smp

What Are the Key Trends Driving Remicade Biosimilar Market Growth?
One significant trend making its mark in the Remicade biosimilar market is product innovation. Leading corporations within the market are creating novel products as a strategy to maintain market dominance. One such example is the launch of Amjevita by Amgen Inc., a biotechnology firm located in the US, in January 2023. Amjevita, a biosimilar of AbbVie's Humira, is intended to replicate the safety and efficacy levels of the original drug, marking it as the first biosimilar to Humira. This biological drug, utilized in treating a range of autoimmune diseases including rheumatoid arthritis and Crohn's disease, will potentially challenge Humira's market share. The financial implications are enormous, as Humira is regarded as one of the costliest drugs worldwide, generating billions annually for AbbVie. Amjevita, costing considerably less, is not only a money-saver but could also present more treatment choices to patients.

What Are the Main Segments in the Remicade Biosimilar Market?
The remicade biosimilar market covered in this report is segmented -

1) By Type: 100mg/10ml, 500mg/50ml
2) By Disease Indication: Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Plaque Psoriasis
3) By Application: Blood Disorders, Oncology Diseases

Subsegments:
1) By 100 Mg/10 Ml: Vials For Injection, Prefilled Syringes
2) By 500 Mg/50 Ml: Vials For Injection, Prefilled Syringes

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11952&type=smp

Which Top Companies are Driving Growth in the Remicade Biosimilar Market?
Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Which Regions Will Dominate the Remicade Biosimilar Market Through 2029?
Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11952

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.